Aarti Drugs Stock Screener | Share Price & Fundamental Analysis
AARTIDRUGS
Pharmaceuticals
Share Price NSE
₹372.30
▲
1.65 (0.45%)
Share Price BSE
₹372.65
▲
1.80 (0.49%)
Track Aarti Drugs share price live with TickJournal's free stock screener.
Analyze Aarti Drugs share price history trends and compare 52-week high low
levels.
Calculate AARTIDRUGS stock fair value using fundamental analysis and view live share price charts.
Determine Aarti Drugs share intrinsic value and compare it with current AARTIDRUGS share price.
Record your Aarti Drugs trades in TickJournal's free trading journal and track your portfolio performance.
Aarti Drugs Market Cap
₹3,392.51 Cr.
EPS (TTM)
₹18.42
Dividend Yield
0.27%
Debt to Equity
0.44
AARTIDRUGS 52 Week High
₹545.05
Aarti Drugs 52 Week Low
₹321.75
Operating Margin
14.00%
Profit Margin
9.28%
AARTIDRUGS Revenue (TTM)
₹679.00
EBITDA
₹95.00
Net Income
₹63.00
Total Assets
₹2,575.00
Total Equity
₹1,369.00
Aarti Drugs Share Price History - Stock Screener Chart
Screen AARTIDRUGS historical share price movements with interactive charts. Analyze price trends and patterns.
Aarti Drugs Company Profile - Fundamental Screener
Screen Aarti Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for AARTIDRUGS shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE767A01016
Aarti Drugs Balance Sheet Screener
Screen AARTIDRUGS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 2,575 | 2,432 | 2,421 | 2,208 | 1,766 | 1,577 | 1,456 | 1,389 | 1,191 | 1,102 |
| Current Assets | 1,338 | 1,321 | 1,492 | 1,393 | 1,057 | 900 | 784 | 737 | 571 | 565 |
| Fixed Assets | 866 | 811 | 676 | 690 | 665 | 644 | 625 | 602 | 581 | 493 |
| Liabilities | ||||||||||
| Total Liabilities | 2,575 | 2,432 | 2,421 | 2,208 | 1,766 | 1,577 | 1,456 | 1,389 | 1,191 | 1,102 |
| Current Liabilities | 368 | 355 | 279 | 232 | 257 | 301 | 321 | 312 | 297 | 244 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 1,369 | 1,282 | 1,193 | 1,036 | 913 | 653 | 543 | 455 | 400 | 357 |
| Share Capital | 91 | 92 | 93 | 93 | 93 | 23 | 24 | 24 | 24 | 24 |
| Reserves & Surplus | 1,278 | 1,190 | 1,100 | 944 | 820 | 629 | 520 | 432 | 376 | 333 |
Aarti Drugs Income Statement Screener - Profit & Revenue Analysis
Screen Aarti Drugs income statement and profit fundamentals.
Analyze AARTIDRUGS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Aarti Drugs share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 679 | 591 | 653 | 603 | 621 | 557 | 600 | 569 | 743 | 662 | 642 | 608 | 697 | 622 | 688 |
| Expenses | 583 | 516 | 569 | 547 | 534 | 490 | 531 | 495 | 649 | 577 | 565 | 536 | 608 | 555 | 614 |
| EBITDA | 95 | 74 | 84 | 56 | 87 | 66 | 69 | 74 | 94 | 85 | 77 | 72 | 89 | 67 | 74 |
| Operating Profit % | 14.00% | 13.00% | 13.00% | 9.00% | 14.00% | 12.00% | 11.00% | 11.00% | 13.00% | 13.00% | 12.00% | 12.00% | 12.00% | 11.00% | 11.00% |
| Depreciation | 15 | 15 | 16 | 18 | 14 | 13 | 14 | 14 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Interest | 9 | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 6 | 7 | 9 |
| Profit Before Tax | 71 | 51 | 60 | 29 | 64 | 44 | 46 | 51 | 73 | 64 | 56 | 52 | 71 | 48 | 53 |
| Tax | 8 | -3 | 15 | -12 | 17 | 11 | 11 | 14 | 17 | 16 | 17 | 15 | 15 | 13 | 14 |
| Net Profit | 63 | 54 | 45 | 41 | 47 | 33 | 35 | 37 | 56 | 48 | 40 | 37 | 55 | 35 | 39 |
| EPS | 6.88 | 5.91 | 4.95 | 4.44 | 5.15 | 3.62 | 3.83 | 4.06 | 6.07 | 5.18 | 4.29 | 3.99 | 5.97 | 3.76 | 4.18 |
Aarti Drugs Cash Flow Screener - Liquidity Fundamentals
Screen AARTIDRUGS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 245 | 359 | 133 | 70 | 155 | 251 | 143 | 70 | 175 | 133 |
| Investing Activities | -165 | -224 | -164 | -150 | -72 | -33 | -62 | -74 | -107 | -99 |
| Financing Activities | -82 | -136 | 17 | 92 | -81 | -215 | -80 | 4 | -68 | -33 |
| Net Cash Flow | -2 | -1 | -14 | 13 | 2 | 2 | 1 | 0 | 0 | 1 |
Aarti Drugs Shareholding Pattern Screener
See Aarti Drugs shareholding pattern with promoter, FII, and DII holdings.
Check Aarti Drugs promoter holding and ownership changes for AARTIDRUGS on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 55.48% | 55.22% | 54.72% | 55.03% | 57.13% | 55.67% | 55.64% | 55.38% |
| FII Holding | 2.25% | 2.26% | 2.69% | 2.15% | 2.56% | 2.96% | 2.50% | 2.28% |
| DII Holding | 9.70% | 9.94% | 9.90% | 10.12% | 5.99% | 7.35% | 7.84% | 8.77% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.51% | 23.69% | 23.58% | 23.43% | 25.11% | 24.75% | 24.80% | 24.32% |
| Other Holding | 9.06% | 8.89% | 9.11% | 9.27% | 9.20% | 9.27% | 9.21% | 9.24% |
| Shareholder Count | 169,761 | 160,260 | 152,252 | 148,363 | 157,547 | 150,218 | 190,281 | 176,006 |
Aarti Drugs Share Dividend Screener - Share Yield Analysis
Check Aarti Drugs dividend history with payout and yield data.
View Aarti Drugs dividend details including ex-dates and amounts for AARTIDRUGS stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.00 | 0.27% |
| 2024-March | ₹1.00 | 0.29% |
| 2023-March | ₹1.00 | 0.23% |
| 2022-March | ₹1.00 | 0.30% |
| 2021-March | ₹2.50 | 0.58% |
| 2020-March | ₹2.00 | 0.29% |
| 2019-March | ₹1.00 | 0.80% |
| 2018-March | ₹1.00 | 0.63% |
| 2017-March | ₹1.00 | 0.79% |
Aarti Drugs Stock Index Membership
See which indices include Aarti Drugs stock.
Check AARTIDRUGS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Aarti Drugs Market Events Screener - Corporate Actions
Get Aarti Drugs corporate actions including splits, bonuses, and buybacks.
Check Aarti Drugs stock events that may affect AARTIDRUGS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Buyback | 900 | 2.86% | ||
| 2020-10-01 | Bonus | 3:1 | 3.97% | |
| Annual General Meeting | NA | 9.35% | ||
| Annual General Meeting | NA | -11.02% | ||
| 2026-02-09 | 2026-02-09 | Dividend | ₹ 2.00 /share | -2.32% |
| 2026-02-03 | 2026-02-03 | Quarterly Result Announcement | NA | 3.65% |
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | -2.61% |
| 2025-07-18 | 2025-07-18 | Quarterly Result Announcement | NA | 7.28% |
| 2025-05-06 | 2025-05-06 | Quarterly Result Announcement | NA | 0.97% |
| 2025-02-04 | 2025-02-04 | Dividend | ₹ 1.00 /share | 8.52% |
| 2025-01-29 | 2025-01-29 | Quarterly Result Announcement | NA | -8.06% |
| 2024-10-24 | 2024-10-24 | Quarterly Result Announcement | NA | -3.19% |
| 2024-02-06 | 2024-02-06 | Dividend | ₹ 1.00 /share | -2.89% |
| 2023-08-04 | 2023-08-09 | Buyback | 900 | 2.45% |
| 2023-02-08 | 2023-02-08 | Dividend | ₹ 1.00 /share | -3.11% |
Aarti Drugs Competitors Screener - Peer Comparison
Screen AARTIDRUGS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 407,287 | 37.56 | 54,729 | 9.71% | 10,980 | 52.49 |
| Divis Laboratories | 163,754 | 66.27 | 9,712 | 18.67% | 2,191 | 48.87 |
| Torrent Pharmaceuticals | 138,018 | 64.55 | 11,539 | 6.99% | 1,911 | 59.36 |
| Cipla | 107,555 | 23.69 | 28,410 | 7.12% | 5,291 | 35.86 |
| Dr Reddys Laboratories | 105,839 | 19.26 | 33,741 | 16.73% | 5,725 | 58.24 |
| Lupin | 100,464 | 23.23 | 22,910 | 13.74% | 3,306 | 56.93 |
| Zydus Life Science | 91,034 | 18.43 | 23,511 | 18.55% | 4,615 | 51.32 |
| Mankind Pharma | 85,058 | 47.59 | 12,744 | 20.90% | 2,007 | 42.02 |
| Aurobindo Pharma | 66,537 | 19.29 | 32,346 | 9.43% | 3,484 | 45.13 |
| Alkem Laboratories | 64,595 | 29.06 | 13,458 | 3.70% | 2,216 | 36.02 |
Aarti Drugs Company Announcements - News Screener
Screen AARTIDRUGS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-02-16 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2026-02-11 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2026-02-03 | Record Date For Interim Dividend | View |
| 2026-02-03 | Corporate Action-Board approves Dividend | View |
| 2026-02-03 | Board Meeting Outcome for Outcome Of Board Meeting | View |
| 2026-02-03 | Financials Results For The Quarter And Nine Months Ended December 31 2025 | View |
| 2026-01-29 | Announcement under Regulation 30 (LODR)-Credit Rating | View |
| 2026-01-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-01-27 | Board Meeting Intimation for Audited Financial Results For The Quarter And Nine Months Ended December 31 2025 And Interim Dividend For The FY 2025-26 If Any | View |
| 2026-01-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-12-29 | Closure of Trading Window | View |
| 2025-11-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |